Sponsored

Prescient (ASX:PTX) reports promising clinical data for PTX-100 in relapsed and refractory TCL - Kalkine Media

March 16, 2023 02:56 PM AEDT | By Team Kalkine Media
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Prescient Therapeutics (ASX:PTX) has updated on continued promising results in PTX-100 T Cell Lymphoma Phase 1b Cohort.
  • The latest data has exhibited two new complete responses in the patients since the last update.
  • The results indicate that 7 of 10 evaluable patients had durations of response exceeding standard of care.
  • The compound continues to exhibit an excellent safety profile, the company says.
  • The company plans to proceed expeditiously to a registration trial.

Prescient Therapeutics Limited (ASX:PTX) has shared an encouraging update for the ongoing clinical trial of its PTX-100 compound in patients with relapsed and refractory T cell lymphomas (TCL).

The compound, which is under the Phase 1b expansion cohort, continues to indicate encouraging clinical activity, with two patients showing complete responses (complete eradication of cancer) since the last update in November 2022. The company says that this observation is not generally expected in this disease (relapsed and refractory peripheral TCL).

Also, the latest update suggests that the compound has shown an excellent safety profile at the highest dose of 2000 mg/m2.

Excellent safety profile and encouraging clinical activity

Under the study at Epworth Hospital in Melbourne, 13 TCL patients received PTX-100 dosing including five patients with cutaneous TCL (CTCL) and eight patients with PTCL.

Safety - The clinical-stage oncology company suggests that the compound continues to display an excellent safety profile on the study.

Neutropenia, thrombocytopenia and anaemia are among the few of the adverse events observed. The adverse events were observed in the same patient; however, they recovered/resolved these events.

It is to be noted that such side effects are not uncommon in treating this patient population and are likely manageable, says the company.

Encouraging clinical activity - PTX-100 continues to exhibit encouraging clinical activity in the difficult-to-treat patient population, especially when considered against responses expected from current standards of care.

The data suggests that 7 of 10 evaluable patients had durations of response exceeding standard of care.

Image source: PTX update  

Prescient to apply for FDA meeting by end-2023   

The company recently secured the additional Orphan Drug Designation from the US FDA for PTX-100. Prescient has been suggested by regulatory advisors to recruit seven additional patients, to get more data for a more meaningful and productive dialogue with the US FDA.

Given satisfactory Phase 1b study results, the company intends to undertake a subsequent Phase 2 trial in TCL.

Data source: PTX update

Also, the company plans to sought clarification on the dose optimisation and dose schedule considerations for the Phase 2 study pursuant to the FDA’s Project Optimus. This project targets maximising drug efficacy along with its tolerability and safety.

Later in 2023, the company will be filling an application for a meeting with the FDA. If successful, the company expects to open the registrational Phase 2 study within a period of one year.

Prescient is already working on planning towards undertaking another manufacturing campaign of PTX100 in order to facilitate further studies. The company will conduct and document the manufacturing process at higher levels of rigour required to support later stage trials and regulatory submissions.

PTX shares were trading at AU$0.120 midday on 16 March 2023. 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



Top ASX Listed Companies


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.